Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
So here are some takeaways on the longevity of the obesity platform: Even without GLP-1 craze they grew the business (profitably?) to a $100M run-rate in 7 months with oral weight loss medications alone We will see a flood of new GLP-1 medications enter the market and the situation will move quickly and be fluid including the introduction of oral compounds that may lead to other use-cases for Hims There is some sort of precedent that compounding certain elements like end-dosage or side effect mitigation is considered clinically necessary and therefore defensible Hims & Hers will also offer brand-name GLP-1s on platform, maybe alluding to expectations of reduction in out of pocket cost over time, or an increase in supply My unsolicited thoughts for Hims would be to take advantage of this huge surge in cash and invest it into the sustainable, growing parts of the business
Drugs like semaglutide and tirzepatide, sold as Ozempic, Wegovy, Mounjaro, and Zepbound, have been studied exhaustively for what they do to blood sugar, appetite, and weight
Whats the Semaxen (Semaglutide)/ OZEMPIC Generic Semaglutide price/ cost in Bangladesh/ Russia/ USA/ UK/ India/ China/ Egypt/ other countries
Neurosci Lett 2014
(n.d.) Research Spotlight: Type 1 diabetes staging classification opens door for intervention
